Bioterrorism threats and infectious disease outbreaks are on the rise. Emergent BioSolutions Inc. (EBS) has a stream of revenues from FDA-approved drugs, as well as a full pipeline of drugs under development, to combat these health threats.
Over 50% of the company’s 2017 revenues come from its BioThrax anthrax vaccinations. In addition to rising anthrax outbreaks in animals, biowarfare is a looming threat. North Korea has 13 bioweapons in stock, of which anthrax is the most likely to be used, says South Korea. EBS is rapidly expanding its product line beyond anthrax to address a range of biological, chemical and emerging disease risks.